ClinicalTrials.gg
RecruitingNCT07260110TEPLI-QUESTUpdated Dec 3, 2025

A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

An observational study in Type 1 Diabetes, sponsored by Sanofi. Recruiting at 1 site in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Sanofi · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
550
Ages
8 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Started
2025
with 5 others
Observational
6 of 67
4 open now
Registered
65th of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is one of 6 that started in 2025, is one of 6 observational ones, and was the 65th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 8 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

This study is an observational, longitudinal, non-interventional real-world study in the United States. The study is meant to describe the experience of participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab and the experience of participants with stage 2 type 1 diabetes who have not been infused with teplizumab, and to compare descriptively the experiences of the two groups.

Primary Objective:

- To characterize health related quality of life, diabetes-related anxiety, diabetes-related burden, and ease of diabetes management, and how participants feel, form and function in those who infused and those who did not infuse with teplizumab

Secondary Objectives:

  • To show the clinical transitions experienced by those who infused and those who did not infuse with teplizumab
  • To describe the prevalence and timing of diabetes misclassification and the temporal patterns between misclassification, antibody testing, and the correct diagnosis of type 1 diabetes in those who infused and those who did not infuse with teplizumab
  • To estimate the impact of diagnostic misclassification on the timing of progression to stage 3 type 1 diabetes in those who infused and those who did not infuse with teplizumab
  • To characterize glucose monitoring strategies in those who infused and those who did not infuse with teplizumab where possible
  • To characterize insulin use in those who infused and those who did not infuse with teplizumab where possible
  • To characterize longitudinal health care resource utilization in those who infused and those who did not infuse with teplizumab
Read the detailed description

Each participant is expected to participate in the study from the time of their enrollment through the last data delivery, which is estimated to occur five years after the first participant is enrolled.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with a history of Stage 2 T1D (documented in medical records) and infused with teplizumab or not infused with teplizumab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of stage 2 type 1 diabetes with the presence of one or more diabetes-related autoantibodies and dysglycemia confirmed in the medical record
  • At the time of enrollment either not yet diagnosed with stage 3 type 1 diabetes, or the progression occurred in the last 18 months prior to enrollment
  • Aged 8 or older at the time of enrollment
  • Aged 8 or older at the time of teplizumab infusion (if infused)
  • Receipt of medical care in the United States
  • Able to and does give written

Exclusion criteria

Exclusion Criteria:

- Failure to complete the baseline survey

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
550 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with a history of teplizumab infusion

    Participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab at the time of enrollment

    Drug: Teplizumab

  • Participants with no history of teplizumab infusion

    Participants with stage 2 type 1 diabetes who have not been infused with teplizumab at the time of enrollment

Interventions

  • This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

    Also known as: TZIELD

06

What researchers measure

Primary outcomes

  1. Change in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions

    Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years

  2. Change in participant and caregiver-reported outcomes from survey responses: Psychological well-being World Health Organization-5 (WHO-5)

    Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years

  3. Change in participant and caregiver-reported outcomes from survey responses: State-Trait Anxiety Inventory (STAI)

    Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years

  4. Change in participant and caregiver-reported outcomes from survey responses: Type 1 Diabetes Distress Assessment System-Core Scale (T1-DDAS CORE)

    Time frame: From baseline, repeated every 6 months, up to end of study, approximately 5 years

  5. Change in participant and caregiver-reported outcomes from survey responses: Diabetes constraints scale

    Time frame: From baseline, repeated every 6 months up to end of study, approximately 5 years

  6. Sociodemographic screening characteristics

    Time frame: At enrollment

  7. Sociodemographic medical history characteristics

    Time frame: At enrollment

  8. Sociodemographic diabetes management characteristics

    Time frame: At enrollment

Secondary outcomes

  1. Changes in characteristics of participants: monitoring practices (e.g. continuous glucose monitor, self-monitoring blood glucose, blood drawn by clinician) across type 1 diabetes stages

    Time frame: From enrollment up to study end, approximately 5 years

  2. Changes in characteristics of participants: medical history across type 1 diabetes stages

    Time frame: From enrollment up to study end, approximately 5 years

  3. Time from index date to the diagnosis of stage 3 type 1 diabetes

    Time frame: From baseline up to end of study, approximately 5 years

  4. Changes in glucose parameters: HbA1c

    Time frame: From baseline up to end of study, approximately 5 years

  5. Changes in glucose parameters: blood glucose

    Time frame: From baseline up to end of study, approximately 5 years

  6. Changes in glucose parameters: post prandial glucose

    Time frame: From baseline up to end of study, approximately 5 years

  7. Changes in glucose parameters: c-peptide

    Time frame: From baseline up to end of study, approximately 5 years

  8. Changes in glucose parameters: time in range in participants with glucose monitor data

    Time frame: From baseline up to end of study, approximately 5 years

  9. Changes in glucose parameters: time above range in participants with glucose monitor data

    Time frame: From baseline up to end of study, approximately 5 years

  10. Changes in glucose parameters: time below range in participants with glucose monitor data

    Time frame: From baseline up to end of study, approximately 5 years

  11. Changes in glucose parameters: glucose variability percent in participants with glucose monitor data

    Time frame: From baseline up to end of study, approximately 5 years

  12. Changes in glucose parameters: percent coefficient of variation in participants with glucose monitor data

    Time frame: From baseline up to end of study, approximately 5 years

  13. Changes in glucose paremeters: glucose management indicator in participants with glucose monitor data

    Time frame: From baseline up to end of study, approximately 5 years

  14. Number of complications (including micro- and macrovascular occurrences and hypoglycemia occurrences)

    Time frame: From baseline up to end of study, approximately 5 years

  15. The frequency of glycemic vs. autoantibody testing related to stage 2 type 1 diabetes diagnosis

    Time frame: At enrollment

  16. The sequence (first or second) of glycemic testing vs. autoantibody testing related to stage 2 type 1 diabetes diagnosis

    Sequence describes if glycemic testing or autoantibody testing took place first in stage 2 type 1 diabetes diagnosis

    Time frame: At enrollment

  17. The frequency of misclassification with type 2 diabetes

    Time frame: At enrollment

  18. The time between misclassification with type 2 diabetes and autoantibody testing

    Time frame: At enrollment

  19. The time between misclassification with type 2 diabetes and the correct diagnosis of stage 2 type 1 diabetes

    Time frame: At enrollment

  20. Time from index date to the diagnosis of stage 3 type 1 diabetes for those misclassified with type 2 diabetes where diagnosis is confirmed by HbA1c and/or glycemic measures

    Time frame: From baseline up to end of study, approximately 5 years

  21. Proportion (%) of participants using home glycemic monitoring assessments (Continuous Glucose Monitor, self-monitoring blood glucose, urine glucose monitoring) vs in-clinic assessments (HbA1c, fasting blood glucose, c-peptide)

    Time frame: From baseline up to end of study, approximately 5 years

  22. Proportion (%) of participants using insulin characterized by insulin dosing, type, regimen, and mode of administration

    Time frame: From baseline up to end of study, approximately 5 years

  23. Annualized rate of hospitalizations due to type 1 diabetes complications

    Time frame: From baseline up to end of study, approximately 5 years

  24. Annualized rate of emergency room visits due to type 1 diabetes complications

    Time frame: From baseline up to end of study, approximately 5 years

  25. Annualized rate of specialist (including endocrinologist) visits

    Time frame: From baseline up to end of study, approximately 5 years

07

Study locations

1 of 1 sites recruiting
  • Investigational Site
    San Francisco, California 94107, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2030, 61 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 61 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Dec 3, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Dec 3, 2030
CompletionEst.
Dec 3, 2030
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07260110
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Oct 31, 2025
Primary completion
Dec 3, 2030 (estimated)
Completion
Dec 3, 2030 (estimated)
Last update
Dec 3, 2025

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6
PicnicHealth For potential study participants
Contact
hello@picnichealth.com
415-680-3085

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion